Akros Pharma

Focus: Akros Pharma develops pharmaceutical products for JT Pharmaceuticals with a focus on neurology and metabolic disease indications. The company operates as a public entity headquartered in Princeton, NJ with a diversified pipeline spanning multiple therapeutic areas.

Neurology

Profile data last refreshed Yesterday · AI intelligence enriched 2w ago

Funding Stage

PUBLIC

Open Jobs

About Akros Pharma

AI assessmentNot Hiring

No open roles listed right now. Follow Akros Pharma to get notified when they start hiring — the background below is worth knowing for when they do.

Why Work Here

Data completeness

2/9 — Limited

Company HealthSolid

Pipeline

Early-stage

16 total

LOE Risk

Protected

No near-term cliffs

Hiring

0 open

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

Pipeline & Clinical Trials

JTK-853

Hepatitis C Virus Infection

Phase 1

Clinical Trials (3)

NCT01473069Two Week Study Evaluating Safety, Tolerability and Pharmacokinetics of Multiple Doses of JTK-853 in Healthy Subjects

Phase 1

Help build intelligence for Akros Pharma

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Diverse pipeline of 16 programs across metabolic, inflammatory, and infectious disease spaces provides exposure to multiple therapeutic areas
Public company status offers potential equity upside and more transparent financial/strategic visibility than private peers
Established partnerships with JT Pharmaceuticals suggest stable development funding and defined go-to-market strategies

Watch Out For

Zero active job openings signals minimal hiring activity and limited near-term career mobility within the organization
No Phase 3 programs in pipeline means no near-term regulatory catalysts or commercial launches to drive growth or bonus upside
Missing financial data (revenue, R&D spend, cash position) creates uncertainty around company stability and long-term viability

Generated by Claude from Akros Pharma's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.

NCT01473056Study to Assess Safety,Tolerability,Pharmacokinetics & Antiviral Activity of JTK-853 in Hepatitis C Virus Genotype 1 Infected Subjects

Phase 1

NCT01475981Safety, Tolerability and Pharmacokinetics Study Assessing Ascending Single Oral JTK-853 Doses in Healthy Subjects

Phase 1

JTZ-951

Anemia of Chronic Kidney Disease

Phase 1

Clinical Trials (4)

NCT01971164Safety, Tolerability, PK & PD Study of JTZ-951 in Anemic Subjects With End-stage Renal Disease

Phase 1

NCT02581124Study to Evaluate Effect of Lapatinib on Pharmacokinetics of JTZ-951 in Subjects With End-stage Renal Disease

Phase 1

NCT01978587Effect of Hemodialysis on the PK of JTZ-951 in Subjects With End-stage Renal Disease

Phase 1

+1 more

JTT-662

Diabetes Mellitus, Type 2

Phase 1

Clinical Trials (1)

NCT04465877Study to Evaluate Safety, Tolerability, Pharmacokinetics & Pharmacodynamics of JTT-662 in Subjects With Type 2 Diabetes

Phase 1

JTT-252

Diabetes Mellitus

Phase 1

Clinical Trials (1)

NCT02120976Study of Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Oral Doses of JTT-252

Phase 1

JTE-162

Cryopyrin-associated Periodic Syndromes (CAPS)

Phase 1

Clinical Trials (1)

NCT07247266Study to Evaluate the Safety, Tolerability, Efficacy and Pharmacokinetics of JTE-162 in Subjects With Cryopyrin-Associated Periodic Syndrome (CAPS)

Phase 1

JTE-051

Rheumatoid Arthritis

Phase 2

Clinical Trials (2)

NCT03358290Study to Evaluate the Safety and Efficacy of JTE-051 in Subjects With Moderate to Severe Plaque Psoriasis

Phase 2

NCT02919475Study to Evaluate Efficacy, Safety and Tolerability of JTE-051 in Subjects With Active Rheumatoid Arthritis

Phase 2

JTT-851

Type 2 Diabetes Mellitus

Phase 2